We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

New COVID-19 Immunity Study Finds Majority of Coronavirus-Infected People Retain Antibodies for Over Six Months

By HospiMedica International staff writers
Posted on 22 Dec 2020
Illustration
Illustration
A new COVID-19 immunity study has found that a very large share of people infected with coronavirus in the spring still had detectable antibodies six months later.

The study by the Finnish Institute for Health and Welfare (THL; Helsinki, Finland) aimed to find out how long the antibodies last in SARS CoV2 virus infected persons, and thus also to assess the duration of possible protection. A previous study by THL and the City of Helsinki had found that nearly all those infected with coronavirus (63/64) formed antibodies, which also remained for a period of four months in most of the participants.

The follow-up study for the serological population study of the coronavirus epidemic began in October. People aged 18 or over, who had a coronavirus infection confirmed by PCR-testing in the spring at least six months prior, were invited to take part in the study. The first blood samples were taken in early November. To date, 1,164 subjects from five different hospital districts have participated in the study. A microneutralization test developed at THL was utilized in the antibody study. The microneutralization test measures antibodies that neutralize the virus. Thus far, these antibodies have been found in 792/867 subjects (91%) in the follow-up study. The THL study found neutralizing antibodies in all 129 COVID-19 patients who had been hospitalized.

Other recent studies have also shown that neutralizing antibodies persist in a large proportion of those infected, despite a decrease in total antibodies in the months following infection. Coronaviruses that cause severe infections, such as SARS and MERS, can produce antibodies that persist for several years. The neutralizing antibodies formed in infected persons are likely to provide protection against symptoms or severe symptoms of a new infection, as evidenced by animal experiments. However, it is not yet known which amount of antibodies is sufficient to protect a person from an infection or how long the protection will last.

"The fact that antibodies persist in such a large proportion of those infected for a long time is a promising finding, and, in particular, the persistence of neutralizing antibodies can mean longer-term protection from new infection," said THL's Research Manager Merit Melin.

"Our observation that neutralizing antibodies persist in most people for more than six months after infection also increases optimism about the long-term protection provided by vaccines," added THL's Research Manager Arto Palmu.

Related Links:
Finnish Institute for Health and Welfare (THL)

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Emergency Ventilator
Shangrila935

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more